DA
SGMO

DCF Advisers’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

DCF Advisers’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-13,100
Closed -$157K – 97
2021
Q2 		$157K Sell
13,100
-900
-6% -$10.2K 0.06% 91
2021
Q1 		$175K Hold
14,000
– – 0.08% 98
2020
Q4 		$218K Sell
14,000
-26,400
-65% -$309K 0.09% 83
2020
Q3 		$382K Sell
40,400
-30,000
-43% -$324K 0.2% 68
2020
Q2 		$631K Buy
70,400
+16,500
+31% +$153K 0.35% 50
2020
Q1 		$343K Hold
53,900
– – 0.22% 54
2019
Q4 		$451K Buy
+53,900
New +$496K 0.29% 57

Other funds holding SGMO

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

DCF Advisers's SGMO Position: Q3 2021 in Review

DCF Advisers sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2021, closing a stake of 13,100 shares — an estimated $157K sold.

DCF Advisers first reported a position in SGMO in Q4 2019 and held it in 7 quarters. The position peaked at $631K in Q2 2020. 193 funds tracked by Wall St. Rank hold SGMO as of Q3 2021.

  • DCF Advisers reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2021 after selling out during the quarter.
  • DCF Advisers sold 13,100 SANGAMO THERAPEUTICS INC shares in Q3 2021, an estimated $157K.
  • DCF Advisers first reported a position in SANGAMO THERAPEUTICS INC in Q4 2019 and held it in 7 quarters.
  • DCF Advisers's SANGAMO THERAPEUTICS INC position peaked at $631K in Q2 2020.
  • 193 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2021.

Based on DCF Advisers's 13F filing for Q3 2021, filed 15 Nov 2021.